Researchers from Université Laval’s Infectious Disease Research Centre (IDRC) have made a breakthrough towards the development of a new vaccine against the Zika virus which will be tested for the first time in humans.
“We’re very proud to be part of the first international team in the world to complete all of the steps in the regulatory process and to be authorized by the Food and Drug Administration (FDA) and Health Canada to develop a Zika vaccine,” said Gary Kobinger, doctor of microbiology, professor in Université Laval’s Faculty of Medicine, researcher with Centre de recherche du CHU, director of IDRC, and a global authority on vaccine research.
To read the press release from Université Laval, click here.